Vanguard Global Advisers
MDGL icon

Vanguard Global Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vanguard Global Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.19M Sell
7,808
-239
-3% -$122K ﹤0.01% 862
2026
Q1 		$4.21M Buy
+8,047
New +$3.84M ﹤0.01% 823

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's MDGL Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Madrigal Pharmaceuticals (MDGL) stake by 3% in Q2 2026, selling an estimated $122K and leaving 7,808 shares worth $4.19M. The position accounts for ﹤0.01% of the portfolio, ranked #862.

Vanguard Global Advisers first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.21M in Q1 2026. 402 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Vanguard Global Advisers held 7,808 shares of Madrigal Pharmaceuticals worth $4.19M as of Q2 2026.
  • Vanguard Global Advisers sold 239 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $122K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #862 holding.
  • Vanguard Global Advisers first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Madrigal Pharmaceuticals position peaked at $4.21M in Q1 2026.
  • 402 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.